



DOCKET No.: TORQ-0002
(103336.00004)

COPY OF PAPERS
ORIGINALLY FILED

PATENT

1614
K5
JUL 8 1902

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Robert F. Hofmann, et al.

Serial No.: 09/822,773

Filed: March 30, 2001

Art Unit: 1614

Examiner: John D. Pak

For: **USES OF TARGETED OXIDATIVE THERAPEUTIC FORMULATION
IN ARTERIOSCLEROSIS**

Commissioner for Patents
Box: NON-FEE AMENDMENT
Washington, D. C. 20231

Sir:

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on August 2, 2002.

Debra A. Pepper

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Office Action mailed July 2, 2002, Applicants hereby elect, without traverse, to prosecute in this application the following disclosed species:

- (i) "peroxidic species" or reaction product from oxidation of alkene, wherein the alkene may be, for example, geranylgeraniol;
- (ii) penetrating solvent such as DMSO;
- (iii) dye containing chelated divalent or trivalent metal such as porphyrin; and

DOCKET No.: **TORQ-0002**
(103336.00004)

PATENT

(iv) aromatic redox compound such as benzoquinone.

Respectfully submitted,

T. Ling Chwang

T. Ling Chwang
Reg. No. 33,590
Jackson Walker L.L.P.
2435 North Central Expressway, Suite 600
Richardson, Texas 75080
Tel: (972) 744-2919
Fax: (972) 744-2909

August 2, 2002

Date